IL37 and psoriasis: While data on HLA-C*06:02 carriage and response to IL-23p19 inhibitors is not available, the fact that our two BLP cases were negative for HLA-C*06:02 may indicate that the IL-23 pathway is active in psoriasis irrespective of HLA-C*06:02 status.